Johnson & Johnson $JNJ Holdings Lowered by Massachusetts Financial Services Co. MA

Key Points

• Massachusetts Financial Services Co. trimmed its stake in Johnson & Johnson by 6.7% in Q4, leaving it with 16,388,566 shares worth about $3.39 billion, making J&J 1.1% of MFS’s portfolio and its 7th largest holding.
• Institutional ownership of J&J is high at 69.55%, while insiders have sold 30,142 shares (≈$7.36M) in the last 90 days, leaving insiders with about 0.16% ownership.
• Wall Street sentiment is broadly positive with an average target of $238.17 (buy-weighted ratings and some raises up to $267); near-term focus is on upcoming Q1 results, while J&J sits at a $573.25B market cap with a P/E of 21.54 and last quarter EPS of $2.46 on $24.28B revenue.

Massachusetts Financial Services Co. MA trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,388,566 shares of the company's stock after selling 1,172,786 shares during the period. Johnson & Johnson makes up 1.1% of Massachusetts Financial Services Co. MA's investment portfolio, making the stock its 7th largest holding. Massachusetts Financial Services Co. MA owned about 0.68% of Johnson & Johnson worth $3,391,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $26,000. Clayton Financial Group LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $28,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson during the 2nd quarter worth $27,000. Stone House Investment Management LLC grew its position in Johnson & Johnson by 58.9% during the 4th quarter. Stone House Investment Management LLC now owns 197 shares of the company's stock worth $41,000 after purchasing an additional 73 shares during the last quarter. Finally, Semmax Financial Advisors Inc. grew its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after purchasing an additional 72 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst price-target increase — J&J had a price-target raise to $267, a near-term bullish signal that can support the stock if earnings and guidance align. Article Title
• Positive Sentiment: Strong Innovative Medicines growth noted by investors/letters — Institutional commentary highlights J&J’s Innovative Medicines momentum as a core growth driver underpinning YTD gains and medium-term earnings resilience. Article Title
• Positive Sentiment: TECNIS PureSee IOL clinical/real-world data spotlight — New data presented at ASCRS highlight adoption potential for J&J’s recently FDA-approved intraocular lens, supporting the company’s ophthalmology growth narrative. Article Title
• Positive Sentiment: Steady index momentum — J&J is being noted for steady momentum within the Russell 1000, which can attract passive/index flows and support valuation. Article Title
• Neutral Sentiment: Q1 preview and analyst expectations — Multiple previews (Seeking Alpha, TipRanks) emphasize tomorrow’s Q1 print and guidance as the main near-term catalyst; analysts expect continued earnings but will watch revenue mix and guidance closely. Article Title Article Title
• Neutral Sentiment: Market backdrop — A broader tech-led rally (Nasdaq) and weekly earnings calendar may lift sentiment for large-cap cyclicals, but J&J’s move will hinge more on its own results than tape action. Article Title Article Title
• Negative Sentiment: Short-term pullback and volatility risk — Recent headlines note a 1.2% pullback and intraday weakness; with Q1 due imminently, any guidance miss or cautious commentary could push shares lower. Article Title
• Negative Sentiment: Comparative pressures from higher-growth peers — Coverage comparing J&J to faster-growth names (e.g., Lilly) frames a valuation-growth tradeoff that could limit upside if investors favor high-growth pharma exposure. Article Title

Johnson & Johnson Stock Performance

Shares of JNJ opened at $238.00 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a market cap of $573.25 billion, a P/E ratio of 21.54, a PEG ratio of 2.38 and a beta of 0.34. The company has a 50-day moving average of $241.44 and a two-hundred day moving average of $215.95. Johnson & Johnson has a 12-month low of $146.12 and a 12-month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JNJ. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. TD Cowen began coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a "buy" rating and a $250.00 price objective on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $255.00 price objective on shares of Johnson & Johnson in a research report on Monday, March 30th. The Goldman Sachs Group reissued a "buy" rating and set a $250.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Leerink Partners raised their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a "market perform" rating in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $238.17.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares of the company's stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.